Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
229.58
Dollar change
-5.27
Percentage change
-2.24
%
IndexRUT P/E- EPS (ttm)-23.08 Insider Own18.43% Shs Outstand19.88M Perf Week4.33%
Market Cap4.89B Forward P/E- EPS next Y-17.86 Insider Trans-3.85% Shs Float17.38M Perf Month18.11%
Income-444.27M PEG- EPS next Q-7.49 Inst Own96.97% Short Float23.98% Perf Quarter-1.29%
Sales0.00M P/S- EPS this Y-38.72% Inst Trans-1.64% Short Ratio8.02 Perf Half Y20.53%
Book/sh42.80 P/B5.36 EPS next Y35.60% ROA-62.81% Short Interest4.17M Perf Year-21.45%
Cash/sh49.70 P/C4.62 EPS next 5Y0.00% ROE-88.78% 52W Range119.76 - 301.00 Perf YTD-0.78%
Dividend Est.- P/FCF- EPS past 5Y-55.24% ROI-45.90% 52W High-23.73% Beta-0.42
Dividend TTM- Quick Ratio9.39 Sales past 5Y0.00% Gross Margin- 52W Low91.70% ATR (14)12.02
Dividend Ex-Date- Current Ratio9.39 EPS Y/Y TTM-27.58% Oper. Margin0.00% RSI (14)53.68 Volatility5.95% 5.14%
Employees376 Debt/Eq0.14 Sales Y/Y TTM- Profit Margin- Recom1.47 Target Price363.86
Option/ShortYes / Yes LT Debt/Eq0.14 EPS Q/Q-74.47% Payout- Rel Volume0.72 Prev Close234.85
Sales Surprise- EPS Surprise-18.64% Sales Q/Q- EarningsMay 07 BMO Avg Volume519.92K Price229.58
SMA205.69% SMA50-1.07% SMA20013.21% Trades Volume374,473 Change-2.24%
Date Action Analyst Rating Change Price Target Change
Apr-22-24Initiated BofA Securities Underperform $150
Mar-15-24Upgrade B. Riley Securities Sell → Neutral $155 → $270
Mar-06-24Initiated Citigroup Buy $382
Feb-26-24Downgrade B. Riley Securities Neutral → Sell $155
Dec-20-22Reiterated Oppenheimer Outperform $170 → $250
Dec-19-22Upgrade Raymond James Underperform → Mkt Perform
Dec-19-22Reiterated Piper Sandler Overweight $203 → $280
Dec-19-22Reiterated H.C. Wainwright Buy $170 → $225
Jul-08-22Downgrade B. Riley Securities Buy → Neutral $131 → $75
Oct-07-21Initiated Jefferies Buy $151
May-24-24 03:17AM
May-21-24 09:45AM
May-17-24 03:08AM
May-15-24 09:19PM
May-10-24 08:51AM
10:53AM Loading…
May-09-24 10:53AM
May-08-24 01:23PM
03:02AM
May-07-24 09:18AM
08:34AM
08:08AM
07:17AM
07:00AM
Apr-24-24 04:00PM
Apr-23-24 08:00AM
06:00AM Loading…
Apr-22-24 06:00AM
Apr-16-24 04:05PM
Apr-15-24 04:28PM
Apr-09-24 08:00AM
Apr-05-24 07:15AM
Apr-04-24 01:55AM
01:54AM
01:54AM
Apr-03-24 04:05PM
08:45AM
Apr-01-24 09:09PM
09:59AM
Mar-29-24 09:00AM
04:43AM
Mar-26-24 09:53AM
06:15AM Loading…
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM
04:47PM
04:12PM
04:04PM
03:15PM
07:00AM
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
03:50PM
02:34PM
01:45PM
12:56PM
12:09PM
10:17AM
10:01AM
09:30AM
07:45AM
05:35AM
Mar-14-24 04:25PM
04:15PM
12:11PM
Mar-09-24 05:52AM
Mar-06-24 04:05PM
Mar-05-24 08:00AM
06:03AM
Feb-28-24 07:01AM
07:00AM
06:45AM
Feb-26-24 04:04PM
10:52AM
Feb-23-24 05:43AM
Feb-21-24 08:00AM
Feb-13-24 01:36PM
Feb-08-24 08:00AM
Feb-06-24 04:05PM
11:29AM
11:28AM
Jan-29-24 08:00AM
02:59AM
Jan-22-24 08:00AM
01:29AM
Jan-04-24 08:00AM
01:21AM
Jan-03-24 04:30PM
Dec-30-23 06:50AM
Dec-22-23 04:30PM
Dec-19-23 01:02PM
10:16AM
Dec-15-23 11:01PM
Dec-07-23 08:45AM
Nov-27-23 04:30PM
09:50AM
Nov-24-23 10:00AM
Nov-21-23 08:00AM
Nov-17-23 10:46AM
Nov-16-23 03:03PM
Nov-15-23 04:45PM
Nov-14-23 10:56AM
Nov-13-23 04:40PM
Nov-10-23 08:00AM
07:30AM
Nov-07-23 04:54AM
Nov-06-23 08:00AM
06:29AM
Nov-04-23 12:16PM
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Waltermire Robert E.Senior VP, Chief Pharma Dev.May 21 '24Sale231.341,036239,6685,500May 23 09:36 PM
CRAVES FRED BDirectorMay 14 '24Option Exercise103.0222,4892,316,844435,851May 16 09:53 PM
CRAVES FRED BDirectorMay 14 '24Sale212.8822,4894,787,404413,362May 16 09:53 PM
FRIEDMAN PAUL ADirectorApr 08 '24Option Exercise9.4526,270248,251212,005Apr 10 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 08 '24Option Exercise9.452,67625,288461,675Apr 10 08:53 PM
FRIEDMAN PAUL ADirectorApr 08 '24Sale246.1926,2706,467,491185,735Apr 10 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 08 '24Sale245.992,676658,258458,999Apr 10 08:53 PM
FRIEDMAN PAUL ADirectorApr 05 '24Option Exercise9.4527,613260,943213,348Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 05 '24Option Exercise9.4527,506259,932486,505Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 05 '24Sale243.4027,6136,721,081185,735Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 05 '24Sale243.3627,5066,693,790458,999Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 04 '24Option Exercise9.4518,710176,810204,445Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 04 '24Option Exercise9.4518,537175,175477,536Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 04 '24Sale242.9618,7104,545,721185,735Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 04 '24Sale242.9118,5374,502,823458,999Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 03 '24Option Exercise9.4527,845263,135486,844Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 03 '24Option Exercise9.4527,407258,996213,142Apr 05 08:50 PM
Taub RebeccaPres., R&D, and CMOApr 03 '24Sale245.1427,8456,825,976458,999Apr 05 08:50 PM
FRIEDMAN PAUL ADirectorApr 03 '24Sale245.1227,4076,718,002185,735Apr 05 08:50 PM
BATE KENNETHDirectorApr 02 '24Option Exercise105.0811,2121,178,15712,410Apr 03 08:44 PM
Daly James MDirectorApr 02 '24Option Exercise105.0810,9121,146,63312,110Apr 03 08:41 PM
BATE KENNETHDirectorApr 02 '24Sale244.4911,2122,741,2191,198Apr 03 08:44 PM
Daly James MDirectorApr 02 '24Sale244.5110,9122,668,0871,198Apr 03 08:41 PM
Daly James MDirectorApr 01 '24Option Exercise100.7921,5772,174,71122,775Apr 03 08:41 PM
BATE KENNETHDirectorApr 01 '24Option Exercise57.9621,2771,233,18722,475Apr 03 08:44 PM
Levy Richard SDirectorApr 01 '24Option Exercise63.9211,000703,16021,298Apr 03 08:47 PM
Daly James MDirectorApr 01 '24Sale257.2421,5775,550,5441,198Apr 03 08:41 PM
BATE KENNETHDirectorApr 01 '24Sale257.2621,2775,473,7791,198Apr 03 08:44 PM
Levy Richard SDirectorApr 01 '24Sale257.4811,0002,832,33510,298Apr 03 08:47 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 15 '23Sale238.502,000477,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Option Exercise87.922,000175,8407,667Dec 18 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 14 '23Buy228.3220,6334,710,8931,793,403Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 14 '23Sale232.502,000465,0005,667Dec 18 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Option Exercise87.922,500219,8008,167Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 13 '23Buy219.3981,15917,805,6841,774,294Dec 14 06:10 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 13 '23Sale225.402,500563,5005,667Dec 14 04:30 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Option Exercise87.921,300114,2966,967Dec 14 04:30 PM
BAKER BROS. ADVISORS LPDirectorDec 12 '23Buy218.3134,5787,548,6161,699,129Dec 14 06:09 PM
Waltermire Robert E.Senior VP, Chief Pharma Dev.Dec 12 '23Sale217.851,300283,2005,667Dec 14 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Option Exercise87.091,00087,09016,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 05 '23Sale227.331,000227,33015,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Option Exercise81.161,800146,09016,801Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselDec 04 '23Sale218.871,800393,96415,001Dec 06 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Option Exercise73.753,000221,25018,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 30 '23Sale204.583,000613,73015,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Option Exercise73.754,000295,00019,001Dec 01 04:30 PM
Lynch Brian JosephSVP and General CounselNov 29 '23Sale199.194,000796,75015,001Dec 01 04:30 PM
BAKER BROS. ADVISORS LPDirectorNov 21 '23Buy188.4764,35012,128,3401,667,104Nov 21 06:15 PM
BAKER BROS. ADVISORS LPDirectorNov 20 '23Buy185.7420,7093,846,5751,607,668Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 17 '23Buy174.7046,3708,100,7041,588,541Nov 21 06:14 PM
BAKER BROS. ADVISORS LPDirectorNov 15 '23Buy161.9715,1992,461,7211,545,775Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy154.0037,6605,799,6531,500,227Nov 15 05:12 PM
BAKER BROS. ADVISORS LPDirectorNov 14 '23Buy156.4234,1885,347,8371,531,757Nov 15 05:13 PM
BAKER BROS. ADVISORS LPDirectorNov 13 '23Buy143.2169,83910,001,3681,465,494Nov 15 05:12 PM